Company intelligence / Profile preview

Aidian

Ownership: Private
Employees: ~300
Development stage: Other

Overview

Aidian’s diagnostic products are CE marked and FDA compliant. Their flagship QuikRead go® system has over 60,000 instruments in use globally. The company focuses on rapid, reliable diagnostics to improve patient care decisions—especially supporting rational antibiotic use to combat antimicrobial resistance. No clinical trial results as they are not a drug developer.

Therapeutic areas: OncologyEndocrinologyInfectious Diseases
Modalities: Diagnostic testsPoint-of-care immunoassaysMicrobiological culture testsHygiene monitoring products
Industry: Protein Biomarker Diagnostics

Partnerships

Meridian Bioscience Inc.

Beyond the preview

Go deeper on Aidian.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aidian.

Explore the full profile